Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA‐approved for
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …

Background The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML)
leads to no response to venetoclax (VEN)–based therapy in more than half of the patients …

Venetoclax (Ven) in combination with hypomethylating agents (HMA) is Food and Drug
Administration-approved therapy for elderly/unfit acute myeloid leukemia (AML) patients …

Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …

The addition of venetoclax to hypomethylating agents (HMA-V) improved the outcome of
patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive …

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …

Venetoclax (ABT-199) is a selective, oral bioavailable inhibitor of BCL-2 that has activity in a
variety of hematologic malignancies. 1-3 BCL-2 expression is high in leukemia stem cells of …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …

Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …